Abstract

Phyllodes tumours are rare and account for 0.4% of all breast tumours. The majority of them tend to be less than 5 cms in size with giant tumours larger than 10 cms being about 20% of these cases. They display a broad range of clinical and pathological behavior and are regarded as falling within the spectrum of fibroepithelial neoplasms. Surgery has been the primary modality of treatment. However the extent of resection and the role of adjuvant radiotherapy and chemotherapy are still controversial. The risk of recurrence is (4.7% - 30%) for benign phyllodes tumour and (30% - 65%) for borderline and malignant phyllodes tumour. A case of giant phyllodes tumour measuring 36 × 30 cm and weighing 6.8 kg is presented, which had recurred following a previous resection 5 years back. The literature is reviewed with regards to pathology, the role of investigations, nature of resection and the risk factors for recurrence and metastasis

Highlights

  • Phylloides tumour (PT) are rare fibroepithelial breast tumours that usually occur in adults and are usually seen in women aged 35 to 55 years with only a few cases reported in men [1,2,3,4]

  • While presenting one of the large giant phyllodes tumour reported in the English literature, the literature is reviewed with regards to its pathology, management and risk factors for recurrence and metastasis

  • The data concerning the prognostic factors of PT are conflicting and both benign and malignant PT could recur or metastasize

Read more

Summary

Introduction

Phylloides tumour (PT) are rare fibroepithelial breast tumours that usually occur in adults and are usually seen in women aged 35 to 55 years with only a few cases reported in men [1,2,3,4]. They are composed of benign epithelial component and a cellular spindle cell stroma forming a leaf like structure [1,2,3,4,5]. While presenting one of the large giant phyllodes tumour reported in the English literature, the literature is reviewed with regards to its pathology, management and risk factors for recurrence and metastasis

Case Report
Findings
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.